Humedix, a Huons Global subsidiary, said it got approvals for both Revitalrex syringe and Revitalrex prefilled syringe, both of which are polydeoxyribonucleotide (PDRN) sodium injections used to regenerate the skin.
Humedix noted that securities firms estimate the global regenerative medicine market to grow 21 percent annually to hit $32 billion by 2018. Against this backdrop, the company expected high growth for PDRN as the injection gains a broader range of applications with its regenerative effect.
The injections are primarily used in aesthetic procedures and regenerative medicine due to its cell regeneration effect, the company said.
The injections are made from raw material made from PDRN extracted from Russian salmon by applying Humedix’s biopolymer technology. The company said that it completed developing the injections for tissue repair and wound treatment following skin graft, starting production in earnest.